GILDGilead Sciences

$151.17+36% 1Y

$151.17

$108.5052 weeks$153.91

GILD in its own filings

Nothing in GILD's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.

527

Events found in the filings · across 3,171 filings · the record starts in 1996

Hard flags: none
Hard flags
Most recent filing: Aug 6, 2026
Most recent filing · Form 10-Q
Record starts: Apr 26, 1996
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Oct 29, 2026
SEC comment-letter activity41 occurrences: 2024-03-11

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Aug 4, 2026Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion.Earnings release · press release
May 20, 2026Supplemental Indenture On May 20, 2026, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into an Eleventh Supplemental Indenture (the …Material agreement entered · Form 8-K
May 7, 2026Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion.Earnings release · press release
Apr 28, 2026As previously disclosed, on February 22, 2026, Gilead entered into an Agreement and Plan of Merger (the “Merger Agreement”), among Parent, the Company and Ravens Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Purchaser”)Regulation FD disclosure · Form 8-K
Feb 23, 2026Agreement and Plan of Merger On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“Parent” or “Gilead”), entered into an Agreement and Plan of Merger (the “Merger Agreement”), among Parent, Arcellx, Inc., a Delaware corporation (the “Company”), and Ravens Sub, Inc., a Delaware corporation and a wholly …Material agreement entered · Form 8-K
Feb 10, 2026Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025.Earnings release · press release
Nov 19, 2025On November 19, 2025, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Deborah H. Telman will no longer serve as Executive Vice President, Corporate Affairs and General Counsel of the Company as of December 5, 2025.Director or officer change · Form 8-K
Oct 30, 2025Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion.Earnings release · press release